Navigation Links
Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:2/8/2011

CAMBRIDGE, Mass., Feb. 8, 2011 /PRNewswire/ -- Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

Vascugel, a novel endothelial cell-based therapy and Pervasis' lead development program, aims to regulate the body's healing response following surgical interventions to create vascular access points which are necessary for ESRD patients undergoing hemodialysis, reducing the need for repeat surgical interventions and improving overall patient outcomes.

FDA established Fast Track to facilitate the development and accelerate the pre-market review of treatments for serious and life-threatening conditions, so that these products can reach approval more rapidly. To receive Fast Track designation, a product must address a serious unmet medical condition, and be supported by strong results from pre-clinical or clinical testing demonstrating the product potential.

Vascugel has demonstrated clinical proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV) access for hemodialysis. In these trials, Vascugel exhibited an excellent safety profile and encouraging efficacy trends were observed, including improved duration of patency (or unimpeded blood flow) and a delay in time to first intervention as compared to placebo.

"The fact that these very sick patients must endure serious complications and repeat surgical procedures so that they can continue undergoing hemodialysis represents a significant unmet medical need—one that Vascugel is uniquely able to address," stated Frederic Chereau, president and CEO of Pervasis. "Fast Track designation from the FDA further validates Vascugel's potential as a safe and effective therapy for patients with end stage renal disease, and will help accelerate the
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
3. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
4. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
5. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
6. China Medicine Corporation Receives Manufacturing License for rADTZ
7. Johnson & Johnson Receives Approval from European Commission
8. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
9. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
10. China Sky One Medical Receives Medical Industry Awards
11. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... y LONDRES, August 29, 2015 ... Anatómica para los sistemas de imagen por ... en Ecografía, tiempos de examen rápidos y un flujo ... mayor confianza diagnóstica en el proceso de detección de ... AEX: PHIA) ha anunciado hoy el lanzamiento europeo de ...
(Date:8/28/2015)... Fla. , Aug. 28, 2015  With the ... reaching deadlier heights, Jacksonville -based ... Philip Hemphill is helping to explain why fentanyl ... is approximately 40 to 50 times more potent than ... recreational users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... Aug. 28, 2015  Delays in the launch ... slow down the decision-making process, resulting in missed ... critical for biopharmaceutical companies to develop a tactical ... for quicker and more meaningful insights. ... LLC, nearly three-quarters of benchmarked study participants use ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Expediting the Pharmaceutical Market Research Process for Faster Insights 2
... -- CEL-SCI,CORPORATION announces that CEL-1000 increased the ... combination with MAS-1, a,water-in-oil adjuvant delivery system. ... by Dr. Daniel Zimmerman, Senior Vice,President of ... Society of Microbiologists 107th annual general meeting ...
... Work Status and,Productivity, WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ ... (DDW), from,long-term extensions of the ACT trials (Active ... moderately to severely active,ulcerative colitis (UC) who had ... the trials maintained,improvement in their clinical symptoms for ...
Cached Medicine Technology:CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response,Against Avian Flu Antigen in Animals 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
(Date:8/29/2015)... ... 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for use ... footage that users can shrink and stretch in the Final Cut Pro X timeline. ... color, brightness, scale, speed, range, and flare attributes with intuitive controls found in the ...
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
(Date:8/28/2015)... ... 28, 2015 , ... The 6th Annual Survivor in the City, Chicago ... yet another accolade to its cadre of widespread support—an official letter of support and ... of the medical community and the University of Illinois at Chicago’s Department of Neurosurgery, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices, recently released Visio Stencils for ... Series, HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... will able to uncover the fate of the lost colony ... more than 100 people settled on the Roanoke Island ... deeds and historical narratives have gathered around 168 surnames that ... of the English trying to colonize the new world. ...
... with bird flu in Indonesia appear healthy, making it difficult ... for humans, an official said Monday. ,Indonesia, ... has been struggling to control H5N1 outbreaks across its vast ... found that chickens infected by bird flu have not been ...
... majority of Britain's casinos on Monday lost its ... the country's gambling industry. The British Casino ... that Labour's policy to create 17 new casinos, ... existing gaming establishments with "blatant unfairness." ...
... Stress not only makes your present life miserable, it drags ... Alzheimers, say researchers. ,Researchers from Rush University ... are anxious or depressed are 40 times more likely to ... is often a transitional stage between normal aging and dementia, ...
... Japanese scientists have created a vaccine for cholera that can ... of the University of Tokyo and his colleagues inserted the ... into a rice plant, whose genome has recently been mapped. ... were fed to mice they provoked immunity from the diarrhea-causing ...
... might be able to conceive at an age generally thought to ... expected to come up in the next decade or so. ... be developed into a pill or an injection to extend the ... a fertility revolution enabling women to wait longer to have a ...
Cached Medicine News:Health News:DNA Link to a Lost Colony 2Health News:Stress- Harms Now And Later 2Health News:Vaccines On Your Plate 2
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... enables a fast, precise patternless edge for ... the TOPCON ALE-X1. The latest advance in ... improved features and functions. High-speed processing, a ... beveled edges, precise three-dimensional frame tracing via ...
... mapping software system enhances clinical evaluations with ... corneal maps. The system offers an enlarged ... refractive and keratometric data, and peripheral keratometric ... subclinical keratoconus as well as pre and ...
... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
Medicine Products: